Tag Archives: Gilead Sciences

Challenges in the March Toward an AIDS-Free Generation

By Ben Comer | Published: August 1, 2012

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.

Posted in Biotech, Events, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Also tagged AIDS, Antiretroviral drug, Bill & Melinda Gates Foundation, conference, HIV, HIV/AIDS, NIAID | Leave a comment

HIV Market Banking on Fixed-Dose Treatments

By George Koroneos | Published: July 8, 2010

The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion in [...]

Posted in R&D | Also tagged Antiretroviral drug, Atripla, Bristol Myers Squibb, Datamonitor, Fixed-dose combination, HIV, Infectious disease | Leave a comment